{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:46:51Z","timestamp":1793249211391,"version":"4.5.0"},"reference-count":19,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>The separation of reactive from malignant mesothelial proliferations is often a difficult morphologic problem. There is contradictory information in the literature on whether methylthioadenosine phosphorylase (MTAP) immunohistochemistry can be used for this purpose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To determine the utility of MTAP immunohistochemistry in distinguishing reactive from malignant mesothelial proliferations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>We stained a tissue microarray containing 20 epithelioid malignant mesotheliomas and 17 reactive mesothelial proliferations. For the mesotheliomas, comparisons were made between MTAP staining and BRCA-associated nuclear protein 1 (BAP1) immunohistochemistry, cyclin-dependent kinase inhibitor 2A (CDKN2A) fluorescence in situ hybridization, and neurofibromin 2 (NF2) fluorescence in situ hybridization, which are established techniques for making this separation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Loss of MTAP was seen in 0 of 17 reactive mesothelial proliferations and 13\/20 (65%) malignant mesotheliomas. Almost all cases with loss showed loss in 100% of mesothelial cells. Background inflammatory and stromal cells served as a positive internal control. CDKN2A fluorescence in situ hybridization on the mesotheliomas showed concordance with MTAP staining in 14 of 17 evaluable cases. BAP1 immunohistochemistry showed loss of nuclear staining in 11 of 20 mesotheliomas (55%). No cases showed loss of NF2. A total of 18 of 20 mesotheliomas (90%) showed loss of either MTAP or BAP1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>In the context of a mesothelial proliferation, loss of MTAP staining is 100% specific for malignant mesothelioma. In this study the combination of MTAP and BAP1 immunohistochemical staining allowed separation of reactive from epithelial malignant mesothelial proliferations in 90% of cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2018-0273-oa","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T13:09:10Z","timestamp":1532956150000},"page":"1549-1553","source":"Crossref","is-referenced-by-count":115,"title":["Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas"],"prefix":"10.5858","volume":"142","author":[{"given":"Kyra B.","family":"Berg","sequence":"first","affiliation":[{"name":"From the Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada (Dr Berg); the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Dacic and Ms Miller); and the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Dr Churg and Mr Cheung)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada (Dr Berg); the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Dacic and Ms Miller); and the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Dr Churg and Mr Cheung)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"Miller","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada (Dr Berg); the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Dacic and Ms Miller); and the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Dr Churg and Mr Cheung)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cheung","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada (Dr Berg); the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Dacic and Ms Miller); and the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Dr Churg and Mr Cheung)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Churg","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada (Dr Berg); the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Dacic and Ms Miller); and the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Dr Churg and Mr Cheung)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2018,7,30]]},"reference":[{"issue":"7","key":"2020081300144040800_i1543-2165-142-12-1549-b01","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2020081300144040800_i1543-2165-142-12-1549-b02","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thor Oncol"},{"issue":"8","key":"2020081300144040800_i1543-2165-142-12-1549-b03","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"issue":"4","key":"2020081300144040800_i1543-2165-142-12-1549-b04","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"issue":"4","key":"2020081300144040800_i1543-2165-142-12-1549-b05","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","volume":"140","author":"Churg","year":"2015","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"2020081300144040800_i1543-2165-142-12-1549-b06","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/pin.12453","article-title":"BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests","volume":"66","author":"Hida","year":"2016","journal-title":"Pathol Int"},{"issue":"5","key":"2020081300144040800_i1543-2165-142-12-1549-b07","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1440-1827.2010.02534.x","article-title":"9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis","volume":"60","author":"Takeda","year":"2010","journal-title":"Pathol Int"},{"issue":"22","key":"2020081300144040800_i1543-2165-142-12-1549-b08","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1158\/1078-0432.CCR-09-1511","article-title":"Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors","volume":"15","author":"Huang","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2020081300144040800_i1543-2165-142-12-1549-b09","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/modpathol.2009.186","article-title":"CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival","volume":"23","author":"Krasinskas","year":"2010","journal-title":"Mod Pathol"},{"issue":"6","key":"2020081300144040800_i1543-2165-142-12-1549-b10","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6B","key":"2020081300144040800_i1543-2165-142-12-1549-b11","doi-asserted-by":"crossref","first-page":"E96","DOI":"10.1111\/j.1365-2559.2012.04196.x","article-title":"The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas","volume":"60","author":"Zimling","year":"2012","journal-title":"Histopathology"},{"issue":"2","key":"2020081300144040800_i1543-2165-142-12-1549-b12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"issue":"24","key":"2020081300144040800_i1543-2165-142-12-1549-b13","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2020081300144040800_i1543-2165-142-12-1549-b14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M","article-title":"Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation","volume":"24","author":"Cheng","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2020081300144040800_i1543-2165-142-12-1549-b15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"2020081300144040800_i1543-2165-142-12-1549-b16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2015","journal-title":"Mod Pathol"},{"issue":"5","key":"2020081300144040800_i1543-2165-142-12-1549-b17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5858\/arpa.2015-0508-LE","article-title":"Immunohistochemistry for NF2, LATS1\/2, and YAP\/TAZ fails to separate benign from malignant mesothelial proliferations","volume":"140","author":"Sheffield","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"2020081300144040800_i1543-2165-142-12-1549-b18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2015.12.012","article-title":"Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma","volume":"51","author":"Andrici","year":"2016","journal-title":"Hum Pathol"},{"issue":"2","key":"2020081300144040800_i1543-2165-142-12-1549-b19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.humpath.2016.10.005","article-title":"Loss of BRCA1-associated Protein 1 (BAP1) expression is rare in non\u2013small cell lung cancer","volume":"60","author":"Owen","year":"2017","journal-title":"Hum Pathol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/142\/12\/1549\/1446449\/arpa_2018-0273-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/142\/12\/1549\/1446449\/arpa_2018-0273-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:34:24Z","timestamp":1764790464000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/142\/12\/article-p1549.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,30]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,7,30]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2018-0273-oa","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,30]]}}}